White Paper: The power of pharmacogenomics – revolutionizing the approach to clinical trials through genetic insights
The bioanalytical lab at Worldwide has been a trusted market leader in bioanalysis for over 15 years. In Worldwide’s recent White Paper, ‘The power of Pharmacogenomics: revolutionizing the approach to clinical trials through genetic insights’, the team presents a comprehensive overview of pharmacogenomics (PGx) and its pivotal role in understanding how genetic variations impact an individual’s response to drugs.
Key highlights from the White Paper include:
- The significance of PGx in supporting post-approval personalized medicine, enhancing drug safety and improving efficacy during clinical trials.
- An in-depth review and summary of key PGx genes and their respective roles.
- A case study from the bioanalytical Lab at Worldwide offering valuable insights into PGx assay procedures, parameters, acceptance criteria and practical applications in clinical trials.
Worlwide’s commitment to excellence in bioanalysis positions them at the forefront of advancements in pharmacogenomics, contributing to the evolution of more personalized and effective approaches in clinical trials.
For more information visit:
This content has been provided by Worldwide Clinical Trials. Check them out on LinkedIn!
In association with:
